CA-ODASEVA
12.9.2019 14:02:14 CEST | Business Wire | Press release
Odaseva , the unified cloud data protection, compliance and operations platform for enterprises running Salesforce as a business-critical application, today announced that it has seen triple year over year growth, and after only seven years of operation, supports a staggering one trillion Salesforce records, with over 10 million enterprise-level internal Salesforce customers.
Odaseva’s explosive growth is in part due to the influx of new data privacy and governance laws such as GDPR or CCPA , demanding that businesses put in place specific regulations such as Data Subject Rights (which stipulates that consumers have the right to access their own private information) and leverage more robust data governance solutions to shield and manage private customer information. Odaseva, which began in 2012 with one client, Schneider Electric, has rapidly increased its enterprise customer base including Toyota France, Robert Half International and GE, offering organizations the ability to augment their existing cloud data protection solutions.
“Comprehensive compliance automation and data protection are essential for organizations coping with increasingly complex and costly privacy regulations as varied as HIPAA, GDPR, CCPA and PIPEDA,” says Sovan Bin, founder and CEO of Odaseva. “As confidential personal data is often distributed across multiple clouds, as well as on-premises data centers, our goal at Odaseva has been to introduce consistency in how audit information is gathered and presented as well as preserved, in order to provide a measure of relief for businesses striving to comply with multiple regulations.
“No other technology vendor today can offer such a unified cloud data governance suite for Salesforce as Odaseva,” Sovan Bin continued.
Recent Investments and Increased Headcount
In 2019, Odaseva raised $11.7m in Series A funding round, which brought the total funding for Odaseva to $14 million. The round was led by Partech with participation from new investor Salesforce Ventures and existing investor Serena. These new investments have allowed Odaseva to direct a portion of the new funding to build on existing sales and technology partnerships with Accenture, Capgemini, CGI, and Deloitte.
In addition, Odaseva has doubled their headcount in the past six months with new hires including a new chief legal officer and a vice president of customer and partner success.
Located in San Francisco and Paris, Odaseva continues to actively recruit in both locations and is looking to expand its operations globally.
Added New Products to Portfolio Line-up:
The hallmark of Odaseva’s solution lies in its compliance automation tools such as GDPR for Salesforce which allows the enterprise to automate a broad range of data procedures from backup to archival, audit, and more in order to comply with industry regulations.
However in 2019 alone, Odaseva announced several new tools to complete their portfolio that have included the following:
- Cockpit AI: With advanced machine learning capabilities, Cockpit AI offers the first predictive capacity management system to help enterprise Salesforce users maximize the value of the platform by automating the process of monitoring and forecasting the use of platform allocations – such as file storage, data storage and API calls on Salesforce
- Vault: Works with the Odaseva platform to help users automatically archive sensitive data that organizations are required to keep for long periods of time in regulated industries such as financial services, healthcare and insurance. Not only will the information be kept safe from any unauthorized users, but Odaseva ensures a data durability level of 99.999999999% over a given year.
- Full Sandbox Anonymization application (FSA) for Salesforce customers . The application works with the Odaseva platform to anonymize all personal information that an organization may put in a Salesforce Full Sandbox – which is an isolated copy of an organization’s Salesforce environment that can be used for training, development and testing.
About Odaseva
For enterprises that leverage Salesforce as a mission-critical application, Odaseva delivers enterprise-class data governance, providing data protection (backup and recovery, archiving, governor limits monitoring), data compliance for regulation requirements such as GDPR and data operations (Salesforce DX data extensions). Odaseva was engineered for Salesforce by Salesforce experts and is endorsed by Salesforce Ventures. Over 10+Million Salesforce Enterprise users from industry-leading companies such as Schneider Electric, Heineken and Robert Half trust Odaseva’s data governance platform.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190912005206/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom